Zacks Investment Research Lowers Chimerix (NASDAQ:CMRX) to Sell

Chimerix (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Separately, ValuEngine raised shares of Chimerix from a “hold” rating to a “buy” rating in a research report on Wednesday, April 29th.

Shares of CMRX opened at $3.13 on Monday. Chimerix has a 1 year low of $1.19 and a 1 year high of $4.40. The stock’s fifty day moving average price is $3.20 and its two-hundred day moving average price is $2.15. The firm has a market cap of $186.72 million, a PE ratio of -1.70 and a beta of 1.90.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The firm had revenue of $1.24 million during the quarter, compared to analysts’ expectations of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%. On average, equities analysts forecast that Chimerix will post -0.88 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Chimerix by 1.1% during the 1st quarter. BlackRock Inc. now owns 3,965,728 shares of the biopharmaceutical company’s stock valued at $5,712,000 after purchasing an additional 42,790 shares during the period. State Street Corp grew its holdings in Chimerix by 13.9% during the 4th quarter. State Street Corp now owns 1,221,900 shares of the biopharmaceutical company’s stock valued at $2,480,000 after buying an additional 148,719 shares in the last quarter. AQR Capital Management LLC grew its holdings in Chimerix by 246.0% during the 4th quarter. AQR Capital Management LLC now owns 1,045,604 shares of the biopharmaceutical company’s stock valued at $2,123,000 after buying an additional 743,424 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Chimerix by 28.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,954,136 shares of the biopharmaceutical company’s stock valued at $5,997,000 after buying an additional 654,509 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Chimerix by 100.3% in the fourth quarter. Barclays PLC now owns 48,868 shares of the biopharmaceutical company’s stock worth $99,000 after buying an additional 24,474 shares in the last quarter. Institutional investors own 48.20% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: What is the FTSE 100 index?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.